Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BMY
- Rev/Share 23.4545
- Book/Share 8.5908
- PB 5.4732
- Debt/Equity 2.9466
- CurrentRatio 1.2789
- ROIC 0.1085
- MktCap 95363848800.0
- FreeCF/Share 6.4431
- PFCF 7.2875
- PE 17.5628
- Debt/Assets 0.5544
- DivYield 0.0525
- ROE 0.3193
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BMY | Cantor Fitzgerald | -- | Neutral | -- | $55 | April 22, 2025 |
| Initiation | BMY | Piper Sandler | -- | Overweight | -- | -- | April 22, 2025 |
| Upgrade | BMY | Jefferies | Hold | Buy | -- | $70 | Dec. 16, 2024 |
| Resumed | BMY | BofA Securities | -- | Neutral | -- | $63 | Dec. 10, 2024 |
| Initiation | BMY | Bernstein | -- | Market Perform | -- | $56 | Oct. 17, 2024 |
News
How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?
Published: July 30, 2025 by: Forbes
Sentiment: Neutral
Bristol Myers Squibb (NYSE:BMY) is scheduled to release its earnings report on Thursday, July 31, 2025. For event-driven traders, examining historical stock performance around earnings announcements can provide valuable insights.
Read More
Will Collaboration With Bain Capital Help BMY Advance Its Pipeline?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets.
Read More
Will These 5 Pharma/Biotech Bigwigs Surpass Q2 Earnings Forecasts?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five biotech and drug companies, MRK, AZN, BMY, ABBV and MRNA, slated to release their second-quarter 2025 results this week.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q2 Earnings?
Published: July 28, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY gears up for Q2 results as growth drugs partially offset legacy declines, cost cuts kick in and new launches gain traction. We recommend investors to wait and watch for now.
Read More
Bristol Myers Gains 6.3% in a Month: Buy, Sell or Hold the Stock?
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY rises 6.3% in a month as investors pin hopes on new drugs to offset pressure from pipeline and patent losses.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Reblozyl Enable BMY to Offset the Impact of Generic Competition?
Published: July 23, 2025 by: Zacks Investment Research
Sentiment: Positive
Reblozyl sales surged 35% in Q1 for BMY, but a failed phase III study clouds expansion plans amid stiff anemia drug competition.
Read More
Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally
Published: July 21, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FDA--BMS's Supplemental New Drug Application for Sotyktu for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review.
Read More
July's 5 Dividend Growth Stocks With Yields Up To 7.96%
Published: July 18, 2025 by: Seeking Alpha
Sentiment: Positive
Dividend growth stocks can offer a stable way to passively grow one's income, creating long-term compounding wealth over the long run. Today, we are looking at a screening process that focuses on higher yields but ranks higher on dividend safety and consistency for growth. From the hundreds that end up listed, we take a look at some of those that rank on the higher yield end for an initial look.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Published: July 17, 2025 by: CNBC
Sentiment: Neutral
Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
Read More
Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients
Published: July 17, 2025 by: Reuters
Sentiment: Positive
US drugmakers Bristol Myers and Pfizer said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at discounted rate through a new program.
Read More
Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option
Published: July 17, 2025 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option.
Read More
Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price
Published: July 17, 2025 by: WSJ
Sentiment: Positive
The joint venture is launching a direct-to-consumer service of Eliquis after discussions with the Trump administration.
Read More
Will Increased Expenses Affect Bristol Myers' Performance?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
Read More
$7.4 Trillion Is in Money Markets Now: When Rates Fall, These High-Yield Blue Chips Will Run
Published: July 14, 2025 by: 24/7 Wall Street
Sentiment: Positive
According to Yahoo Finance, the average annual percentage yield for high-yield money market accounts is currently around 4.30%, with some banks offering rates exceeding 5.00%.
Read More
ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Negative
AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.
Read More
Will Recent Label Expansions of Opdivo Help BMY Gain Momentum?
Published: July 09, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY leans on Opdivo's solid growth and new approvals as generics pressure its other top drugs and shares remain under pressure.
Read More
Healthy Returns: Medicaid cuts in Trump's megabill may affect some drugmakers more than others
Published: July 08, 2025 by: CNBC
Sentiment: Negative
Trump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read More
2 Wonderful Dividends At Bargain Basement Prices
Published: July 07, 2025 by: Seeking Alpha
Sentiment: Positive
Uncertainty creates value opportunities. In this article, I highlight two value stocks trading far below their historical valuations. Both offer dividend yields that are well above historical average and strong growth potential. Both stocks exemplify how investors can secure decent yields and future upside by buying quality companies when market sentiment is overly pessimistic.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: July 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
Read More
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Negative
BMY loses 16.3% YTD as pipeline setbacks and generic pressure offset gains from new drug approvals and sales.
Read More
This Once Dominant Dividend Stock May Be About to Come Back to Life in July
Published: June 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
For income investors seeking a timely value stock to buy on the dip, former dividend darling Bristol-Myers Squibb (NYSE:BMY) may fit the bill as one of the top names to watch in the month of July.
Read More
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
Published: June 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
BMY depends on Reblozyl, Opdualag and Breyanzi to offset revenue hits from generics and Medicare Part D impacts.
Read More
Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst
Published: June 24, 2025 by: Reuters
Sentiment: Negative
Cigna sued Bristol Myers on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst.
Read More
10 'Safer' Dividend Buys Of Barron's Better Bets Than T-Bills For June
Published: June 24, 2025 by: Seeking Alpha
Sentiment: Positive
Long-term bond yields continue to rise. But investors looking for income can still find plenty of attractive opportunities with dividend-paying stocks that have healthy yields. “23 stocks pay huge dividends. They should be a better bet than treasuries.” — Barron's Weekly. In Barron's, Steven Wieting, strategist at Citi Wealth, noted that a growing dividend is a tangible benefit for shareholders and a hallmark of companies with strong balance sheets. "Nobody can fake a dividend," he said.
Read More
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Published: June 20, 2025 by: Zacks Investment Research
Sentiment: Neutral
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
Read More
BMY Focuses on Label Expansion of Drugs: Will This Revive Growth?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
BMY's banks on label expansion of drugs like Sotyktu and Opdivo to boost sales in the wake of generic competition for legacy drugs.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100